ReviewArchives of microbiology2025
Pretomanid for the treatment of drug resistant pulmonary tuberculosis: a comprehensive review.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Characterization of Novel Mycobacteriophages of Subcluster A3: Evolutionary Plasticity of the Lysogeny Module and Lytic Potential.International journal of molecular sciences · 2026Article
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.Microorganisms · 2026Review
- Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles inFrontiers in cellular and infection microbiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pretomanid, a novel nitroimidazoles or nitroimidazooxazines, was recently approved as part of BPaL (Bedaquiline, Pretomanid, and Linezolid) regimen for treating extensively drug-resistant (XDR) and treatment-intolerant/ nonresponsive multidrug-resistant (MDR) cases of pulmonary tuberculosis (TB). It offers new hope in the global fight against drug-resistant TB, which remains a major health challenge. However, the pursuit of better treatment outcomes has been confronted by the rapid emergence of resistance to these drugs. Resistance to pretomanid has been documented in both laboratory and clinical isolates of Mycobacterium tuberculosis. The identification of pretomanid-resistant strains of Mycobacterium tuberculosis highlights the need for judicious use, continuous surveillance and monitoring of pretomanid resistance in TB control programs to prevent further resistance development and ensure the continued success of pretomanid in treating drug-resistant TB. Although genetic mutations associated with pretomanid resistance have been identified in key genes such as ddn and fgd1 of Mycobacterium tuberculosis, the insights into the molecular mechanisms of pretomanid resistance are still quite limited. The better understanding of resistance patterns and molecular mechanisms underpinning pretomanid resistance is crucial for the establishment of uniform phenotypic DST methods and the development of molecular tools for rapid identification/ surveillance of pretomanid resistance. The present review explores the role of pretomanid in treating MDR and XDR-TB cases and provides an updated overview of the pharmacological properties, mechanisms of action, clinical efficacy, and the impact of resistance on the long-term effectiveness of pretomanid in TB treatment regimens.
Indexed as
Identifiers
41263908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.